Article
HLA-B alleles confer susceptibility to sulfasalazine-induced severe cutaneous adverse reactions.
The Journal of allergy and clinical immunology - 1 Sept 2026
Wang Chuang-Wei, Chen Wei-Ti, Chen Chun-Bing, Chu Chia-Yu, Chung-Yee Hui Rosaline, Lu Chun-Wei, Chiu Tsu-Man, Hung Shuen-Iu, Huei Huang Yu, Tassaneeyakul Wichittra, Choon Siew-Eng, Nakkam Nontaya, Sukasem Chonlaphat, Jan Wu Yeong-Jian, Chung Hsin-Yu, Lung Jr-Hau, Chang Jeng-Shou, Lee Yun-Shien, Chang Ya-Ching, Yu Kuang-Hui, Teng Yu-Chuan, Lin Shang-Hung, Lai Kuo-Chu, Hou Hsin-Han, Wu Jennifer, Chi Min-Hui, Lee Hua-En, Yu-Wei Lin Yang, Lin Yu-Jr, Chung Wen-Hung
Abstract excerpt
BACKGROUND: Sulfasalazine is a disease-modifying antirheumatic drug used to treat arthritis and ankylosing spondylitis. However, it may cause life-threatening severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. OBJECTIVE: Genetic predisposition to sulfasalazine-induced SCARs was assessed. METHODS:...
Read the complete abstract on PubMedTopics
- Humans
- Sulfasalazine
- Genetic Predisposition to Disease
